Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of TQB3616 plus fulvestrant versus placebo plus fulvestrant in previously treated HR-positive, HER2-negative advanced breast cancer
CTR20213271Phase 3Active
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of culmerciclib in breast cancer, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Mar 2022; status: active.
02
Drugs
culmerciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20213271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213271.